RMTI on Nasdaq
Rockwell Medical Inc.
Logo: rockwellmed.com4
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Viridian Therapeutics, Inc.\DE, Kura Oncology or Zentalis Pharmaceuticals, Inc., or pick any stock.
- TickerRMTI on Nasdaq1
- Industrypharmaceutical industry1
- HeadquartersUnited States1
- Websitewww.rockwellmed.com
- Incorporated inDE5
- Business address30142 Wixom Road, Wixom, Mi 483935
- Filer categoryNon-accelerated filer, Smaller reporting company5
See how the biggest companies compare on our leaderboards
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 87% of the revenue Rockwell Medical Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $92.3M | $60.4M |
| Outside the United States | $9.2M | $8.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue83¢$57.6M
- Other costs17¢$11.7M
Out of $69.3M in revenue.8 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Sales | $69.3M | $101.5M |
| Cost of Sales | $57.6M | $84.0M |
| Gross Profit | $11.7M | $17.5M |
| Research and Product Development | $0 | $19.0K |
| Selling and Marketing | $2.4M | $2.7M |
| General and Administrative | $14.0M | $14.1M |
| Operating (Loss) Income | -$4.7M | $608.0K |
| Realized Gain on Available-for-Sale Investments | $267.0K | $74.0K |
| Interest Expense | -$1.1M | -$1.3M |
| Interest Income | $234.0K | $92.0K |
| Total Other Expense, net | -$623.0K | -$1.1M |
| Net Loss | -$5.3M | -$480.0K |
| Net Loss Per Share Attributable to Common Stockholders - Basic (in dollars per share) | -$0.15 | -$0.03 |
| Net Loss Per Share Attributable to Common Stockholders - Diluted (in dollars per share) | -$0.15 | -$0.03 |
| Weighted Average Number of Shares of Common Stock Outstanding - Basic (in shares) | 36.0M shares | 31.1M shares |
| Weighted Average Number of Shares of Common Stock Outstanding - Diluted (in shares) | 36.0M shares | 31.1M shares |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and Cash Equivalents | $10.7M | $15.7M | |
| Investments Available-for-Sale | $14.3M | $5.9M | |
| Accounts Receivable, net | $8.1M | $8.3M | |
| Inventory, net | $3.4M | $5.8M | |
| Prepaid and Other Current Assets | $1.6M | $1.4M | |
| Total Current Assets | $38.2M | $37.0M | |
| Property and Equipment, net | $4.6M | $5.8M | |
| Inventory - Non-Current | $0 | $178.0K | |
| Right of Use Assets - Operating, net | $2.6M | $3.2M | |
| Right of Use Assets - Finance, net | $651.0K | $1.3M | |
| Intangible Assets, net | $9.7M | $10.2M | |
| Goodwill | $921.0K | $921.0K | |
| Other Non-Current Assets | $556.0K | $528.0K | |
| Total Assets | $57.1M | $59.2M | |
| Accounts Payable | $2.0M | $2.9M | |
| Accrued Liabilities | $4.3M | $6.3M | |
| Deferred Consideration - Current | $1.0M | $2.4M | |
| Lease Liabilities - Operating - Current | $1.2M | $1.6M | |
| Lease Liabilities - Finance - Current | $469.0K | $599.0K | |
| Deferred License Revenue - Current | $0 | $46.0K | |
| Insurance Financing Note Payable | $264.0K | $268.0K | |
| Customer Deposits | $356.0K | $97.0K | |
| Total Current Liabilities | $9.6M | $14.1M | |
| Lease Liabilities - Operating - Long-Term | $1.5M | $1.7M | |
| Lease Liabilities - Finance - Long-Term | $304.0K | $931.0K | |
| Term Loans - Long-Term, Net of Issuance Costs | $8.8M | $8.5M | |
| Deferred License Revenue - Long-Term | $0 | $429.0K | |
| Deferred Consideration - Long-Term | $0 | $1.0M | |
| Total Liabilities | $20.2M | $26.6M | |
| Preferred Stock, $0.0001 par value, 2,000,000 shares authorized, 15,000 shares issued and outstanding at both December 31, 2025 and 2024 | $0 | $0 | |
| Common Stock, $0.0001 par value, 170,000,000 shares authorized, 39,405,302 and 34,056,920 shares issued and outstanding at December 31, 2025 and 2024, respectively | $4.0K | $3.0K | |
| Additional Paid-in Capital | $439.8M | $430.2M | |
| Accumulated Deficit | -$403.0M | -$397.7M | |
| Accumulated Other Comprehensive Income | $131.0K | $54.0K | |
| Total Stockholders Equity | $37.0M | $32.6M | $21.3M |
| Total Liabilities and Stockholders Equity | $57.1M | $59.2M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | |
| Preferred stock, shares issued (in shares) | 15.0K shares | 15.0K shares | |
| Preferred stock, shares outstanding (in shares) | 15.0K shares | 15.0K shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 170.0M shares | 170.0M shares | |
| Common stock, shares issued (in shares) | 39.4M shares | 34.1M shares | |
| Common stock, shares outstanding (in shares) | 39.4M shares | 34.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Loss | -$5.3M | -$480.0K |
| Depreciation and Amortization | $2.2M | $2.2M |
| Stock-based Compensation | $1.8M | $1.3M |
| Write-off of Inventory | $178.0K | $0 |
| Change in Inventory Reserves | -$425.0K | $425.0K |
| Non-cash Lease Expense from Right of Use Assets | $2.1M | $2.0M |
| Amortization of Debt Financing Costs and Accretion of Debt Discount and Premium | $354.0K | $426.0K |
| Loss on Disposal of Assets | $57.0K | $0 |
| Realized Gain on Sale of Investments | -$267.0K | -$74.0K |
| Gain on Early Termination of Lease Liability | -$24.0K | $0 |
| Provision for Credit Losses | $246.0K | $0 |
| Accounts Receivable | -$98.0K | $2.6M |
| Inventory | $2.8M | -$332.0K |
| Prepaid and Other Assets | $392.0K | $374.0K |
| Accounts Payable | -$870.0K | -$1.6M |
| Lease Liabilities | -$1.7M | -$1.5M |
| Accrued and Other Liabilities | -$1.7M | -$1.0M |
| Deferred License Revenue | -$475.0K | -$46.0K |
| Changes in Operating Assets and Liabilities | -$1.6M | -$1.5M |
| Net Cash (Used In) Provided by Operating Activities | -$659.0K | $4.2M |
| Purchases of Investments Available-for-Sale | -$24.2M | -$5.9M |
| Proceeds from Sales of Investments Available-for-Sale | $16.2M | $2.0M |
| Purchases of Equipment | -$542.0K | -$1.0M |
| Net Cash Used In Investing Activities | -$8.5M | -$4.9M |
| Payments on Insurance Financing Note Payable | -$664.0K | -$646.0K |
| Payments on Finance Lease Liabilities | -$529.0K | -$558.0K |
| Proceeds from Issuance of Common Stock | $7.8M | $10.2M |
| Deferred Consideration Paid in Connection with Evoqua Asset Acquisition | -$2.4M | -$1.6M |
| Net Cash Provided By Financing Activities | $4.3M | $7.3M |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | $0 | -$5.0K |
| Net (Decrease) Increase in Cash and Cash Equivalents | -$5.0M | $6.7M |
| Cash Paid for Interest | $772.0K | $847.0K |
| Issuance of Warrant in Connection with the Third Amendment as Debt Issuance Costs | $0 | $247.0K |
| Right of Use Assets - Operating Obtained in Exchange for Lease Liabilities - Operating | $1.0M | $2.0M |
| De-recognition of Lease Liability - Finance and Right of Use Asset - Finance Upon Early Termination | $228.0K | $0 |
| Change in Unrealized Gain on Investments Available-for-Sale | $77.0K | $60.0K |
| Increase in Prepaid Assets from Insurance Financing Note Payable | $660.0K | $670.0K |
Leadership
Who has led Rockwell Medical Inc., and when. Pick a name to see everywhere that person has worked.
Board members and other officers (1)
- Chief scientific officerAjay Gupta Jul 1, 2009 to Jan 19, 20211
Products and brands
Triferic
Triferic was approved by the Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transports it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market. In February 2014, the Company completed its long-term safety study for Triferic.
Rockwell Medical began commercializing Triferic (dialysate) and Triferic AVNU (intravenous) in the United States in the second half of 2019 and in early 2021, respectively. Triferic was launched into a very competitive marketplace with well-entrenched products and a lack of consensus regarding unmet medical needs for dialysis patients with anemia. Due to its limited market adoption, unfavorable reimbursement, and absence of interest from other companies to license or acquire Triferic despite Rockwell's significant effort to partner the program, Rockwell Medical discontinued its New Drug Applications (“NDAs”) for Triferic and Triferic AVNU in the United States in the fourth quarter of 2022.
Calcitriol
Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.
Hemodialysis Concentrates
Rockwell is a manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient's bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.
Read the full text
Iron (III) pyrophosphate
One of the main treatments that the company develops is iron (III) pyrophosphate, for iron supplementation, a key element in the formation of new red blood cells. It was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis since the process accounts for treatment in around 90% of anemia patients.
International Partnerships
While Rockwell has discontinued commercialization of Triferic in the United States, the company has established international partnerships with companies seeking to develop and commercialize Triferic outside the United States and is working closely with these international partners to develop and commercialize Triferic in their respective regions.
South Korea for example; Triferic and Triferic AVNU have been approved in South Korea, and our partner, Jeil Pharmaceutical, launched Triferic in South Korea during the third quarter of 2022.
Also, in April 2023, Drogsan submitted a Marketing Authorization application and GMP application for Triferic AVNU to the Turkish Medicines and Medical Devices Agency ("TMMDA"), for which Drogsan received priority status and high priority status, respectively. Taking into consideration that Drogsan was granted an accelerated review for Triferic AVNU with the Turkish regulatory authority, Rockwell anticipates approval for Triferic AVNU in Turkey in 2024. Drogsan is responsible for all regulatory approval and commercialization activities.
From Wikipedia’s article on Rockwell Medical, shared under CC BY-SA 4.0.6
Former names
- ROCKWELL MEDICAL TECHNOLOGIES INCJul 24, 1997 to Jun 14, 20125
Timeline
Recent filings
- Oct 5, 20264
- Oct 1, 2026144
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Aug 13, 20268-K
- Jul 20, 20268-K
- Jul 6, 20264
- Jul 6, 20264
- Jul 6, 20264
- Jul 6, 20264
- Jul 6, 20264
- Jul 6, 20264
- Jul 6, 20264
- Jul 6, 20264
- Jul 6, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.rockwellmed.com1
- WikipediaRockwell Medical
- WikidataQ17131128
- SEC EDGARCIK 1041024
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3WikipediaRockwell Medical Inc. on Wikipedia
- 4Company websiteRockwell Medical Inc. logo
- 5
- 6
- 7Wikimedia CommonsRockwell Medical Inc. photo by Rockwell Medical, Public domain
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15